GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (NAS:AFIB) » Definitions » Beneish M-Score

Acutus Medical (Acutus Medical) Beneish M-Score : -4.74 (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.74 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Acutus Medical's Beneish M-Score or its related term are showing as below:

AFIB' s Beneish M-Score Range Over the Past 10 Years
Min: -4.74   Med: -0.3   Max: 28.07
Current: -4.74

During the past 6 years, the highest Beneish M-Score of Acutus Medical was 28.07. The lowest was -4.74. And the median was -0.30.


Acutus Medical Beneish M-Score Historical Data

The historical data trend for Acutus Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical Beneish M-Score Chart

Acutus Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - 1.72 -2.32 28.07 -4.74

Acutus Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.07 8.29 3.64 -4.54 -4.74

Competitive Comparison of Acutus Medical's Beneish M-Score

For the Medical Devices subindustry, Acutus Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acutus Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Acutus Medical's Beneish M-Score falls into.



Acutus Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Acutus Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2123+0.528 * 1.4393+0.404 * 0.9106+0.892 * 2.3639+0.115 * 1.001
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2929+4.679 * -0.564103-0.327 * 2.3218
=-4.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $11.35 Mil.
Revenue was -7.532 + 5.238 + 5.289 + 4.17 = $7.17 Mil.
Gross Profit was 5.614 + -3.357 + -2.774 + -2.62 = $-3.14 Mil.
Total Current Assets was $46.25 Mil.
Total Assets was $53.96 Mil.
Property, Plant and Equipment(Net PPE) was $4.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.87 Mil.
Selling, General, & Admin. Expense(SGA) was $14.07 Mil.
Total Current Liabilities was $18.94 Mil.
Long-Term Debt & Capital Lease Obligation was $35.90 Mil.
Net Income was -33.765 + -13.237 + -18.346 + -16.315 = $-81.66 Mil.
Non Operating Income was 5.087 + 3.284 + 1.082 + 2.441 = $11.89 Mil.
Cash Flow from Operations was -18.013 + -14.008 + -14.582 + -16.515 = $-63.12 Mil.
Total Receivables was $22.62 Mil.
Revenue was -8.37 + 3.644 + 4.076 + 3.681 = $3.03 Mil.
Gross Profit was 10.278 + -3.307 + -5.621 + -3.26 = $-1.91 Mil.
Total Current Assets was $117.87 Mil.
Total Assets was $133.44 Mil.
Property, Plant and Equipment(Net PPE) was $5.54 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.21 Mil.
Selling, General, & Admin. Expense(SGA) was $20.32 Mil.
Total Current Liabilities was $19.87 Mil.
Long-Term Debt & Capital Lease Obligation was $38.54 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11.353 / 7.165) / (22.622 / 3.031)
=1.584508 / 7.463543
=0.2123

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-1.91 / 3.031) / (-3.137 / 7.165)
=-0.630155 / -0.437823
=1.4393

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (46.252 + 4.014) / 53.96) / (1 - (117.867 + 5.541) / 133.44)
=0.068458 / 0.07518
=0.9106

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.165 / 3.031
=2.3639

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.208 / (1.208 + 5.541)) / (0.874 / (0.874 + 4.014))
=0.178989 / 0.178805
=1.001

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.067 / 7.165) / (20.315 / 3.031)
=1.963294 / 6.702408
=0.2929

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((35.897 + 18.942) / 53.96) / ((38.537 + 19.872) / 133.44)
=1.01629 / 0.437717
=2.3218

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-81.663 - 11.894 - -63.118) / 53.96
=-0.564103

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Acutus Medical has a M-score of -4.74 suggests that the company is unlikely to be a manipulator.


Acutus Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Acutus Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Acutus Medical (Acutus Medical) Business Description

Traded in Other Exchanges
N/A
Address
2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
Executives
Takeo Mukai officer: Interim CFO C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland director 10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews officer: SVP, Global Sales C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello officer: Chief People Officer 2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn officer: SVP, Gen. Counsel & Secretary 2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan director C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman officer: SVP & Chief Financial Officer ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008